AstraZeneca said a lab-study of its COVID-19 antibody cocktail, Evusheld, found that the treatment retained neutralising activity against the Omicron coronavirus variant, showing promise for wider use of the therapy.
The study was conducted by independent investigators of the U.S. Food and Drug Administration, the company said, adding that more analyses of Evusheld against Omicron are being conducted by AstraZeneca and third-parties, with data expected “very soon”.
US Secretary of State Antony Blinken’s ongoing visit to Israel is taking place in a period of intense crisis aggravated...
Read more![Local residents remove debris from a house of their neighbour damaged by a Russian military strike, amid Russia's attack on Ukraine, in the town of Hlevakha, outside Kyiv, Ukraine [Valentyn Ogirenko/Reuters]](https://i0.wp.com/www.orissapost.com/wp-content/uploads/2023/01/UK.webp?resize=360%2C180&ssl=1)
As military and humanitarian aid worth billions of dollars keep pouring into Ukraine during its ongoing war against Russia, there...
Read more
Prime Minister Narendra Modi’s assertion in Rajasthan January 28 that several attempts were made to “break India geographically, culturally, socially...
Read more
Readers may be familiar with the fall in the Adani group’s share prices last week. Indian investors were reacting to...
Read more
